Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569114 | 0.80 | LMNA (0.48) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL28769055 | 0.79 | HTR2A (0.42) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL28769054 | 0.79 | HTR2A (0.42) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL2311776 | 0.77 | APP (0.50) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL1657802 | 0.77 | APP (0.50) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL1657799 | 0.77 | APP (0.50) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL614604 | 0.77 | KMT2A (0.42) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL13962950 | 0.76 | LMNA (0.40) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL31605811 | 0.76 | CYP1A2 (0.48) | HTR2ALMNAKMT2AFFAR1APP | |
| SCHEMBL12003637 | 0.76 | MMP12 (0.43) | HTR2ALMNAKMT2AAPPAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | HTR2A 2066/4885LMNA 1905/4885KMT2A 2539/4885 |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | HTR2A 2066/4885LMNA 1905/4885KMT2A 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.